Figure S1. Immunohistochemistry for the specificity of anti-PALB2 antibodies. Surgical samples from stomach (upper panels) and breast cancer (lower panels) were analyzed by immunohistochemistry (magnification, x400; n=3 patients per group).
Figure S2. Inhibition of PALB2 expression in pancreatic ductal adenocarcinoma cells. (A) Reverse transcription-quantitative PCR indicated successful PALB2-knockdown by siRNA in PANC1 and CFPAC1 cell lines. (B) Migration analysis of cells following PALB2-knockdown as determined by a wound healing assay (magnification, x100). (C) Cell proliferation rates were not affected by PALB2-knockdown in PANC1 cells. (D) PALB2-knockdown suppressed cell proliferation in CFPAC1 cells. Biological triplicates were analyzed using an unpaired Student's t-test. *P<0.05; ***P<0.001. OD, optical density; NC, negative control; siRNA, small interfering RNA; PALB2, partner and localizer of BRCA2.
Table SI. Distribution of the IHC scores among PDAC (n=157) and peritumoral tissues (n=121).

| IHC score | PDAC tissues, n (%) | Peritumor tissues, n (%) |
|-----------|---------------------|-------------------------|
| 0         | 93 (59.2)           | 91 (75.2)               |
| 1         | 26 (16.6)           | 27 (22.3)               |
| 2         | 22 (14.0)           | 2 (1.7)                 |
| 3         | 7 (4.5)             | 0 (0.0)                 |
| 4         | 9 (5.7)             | 1 (0.8)                 |

IHC, immunohistochemistry; PDAC, pancreatic ductal adenocarcinoma.
Table SII. Clinicopathological characteristics of 178 patients with PDAC and PALB2 expression in PDAC samples represented in The Cancer Genome Atlas database (May 2019).

| Features                        | High PALB2 expression, n=89 | Low PALB2 expression, n=89 | P-value |
|---------------------------------|-------------------------------|---------------------------|---------|
| Mean age ± SD, years            | 65.8±11.0                     | 63.4±10.8                 | 0.1393  |
| Sex, n (%)                      |                               |                           | 0.4513  |
| Male                            | 46 (51.7)                     | 52 (58.4)                 |         |
| Female                          | 43 (48.3)                     | 37 (41.6)                 |         |
| TNM staging, n^a (%)            |                               |                           | 0.0099^b|
| T1-2                            | 9 (10.0)                      | 22 (25.0)                 |         |
| T3-4                            | 79 (90.0)                     | 66 (75.0)                 |         |
| N stage, n^a (%)                |                               |                           | 0.8661  |
| N0                              | 24 (27.2)                     | 27 (39.7)                 |         |
| N1                              | 64 (63.8)                     | 61 (60.3)                 |         |
| AJCC staging, n^a (%)           |                               |                           | 0.6151  |
| I-IIA                           | 23 (26.1)                     | 26 (29.5)                 |         |
| IIB-IV                          | 65 (73.9)                     | 62 (70.5)                 |         |
| Tumor location, n (%)           |                               |                           | >0.9999 |
| Head                            | 69 (77.5)                     | 70 (78.6)                 |         |
| Body/Tail                       | 20 (22.5)                     | 19 (21.4)                 |         |

^a n=176. ^b P<0.05. PDAC, pancreatic ductal adenocarcinoma; PALB2, partner and localizer of BRCA2.